Edition:
United States

Innoviva Inc (INVA.OQ)

INVA.OQ on NASDAQ Stock Exchange Global Select Market

13.28USD
14 Dec 2017
Change (% chg)

$-0.08 (-0.60%)
Prev Close
$13.36
Open
$13.41
Day's High
$13.50
Day's Low
$13.27
Volume
326,536
Avg. Vol
242,834
52-wk High
$14.87
52-wk Low
$10.30

Latest Key Developments (Source: Significant Developments)

GSK and Innoviva announce positive data from COPD study
Wednesday, 1 Nov 2017 07:00am EDT 

Nov 1 (Reuters) - Glaxosmithkline Plc :GSK STUDY DEMONSTRATES SUPERIORITY OF ANORO ELLIPTA TO STIOLTO RESPIMAT IN IMPROVING LUNG FUNCTION IN CHRONIC OBSTRUCTIVE PULMONARY DISEASE.GSK - ‍POSITIVE DATA FROM A STUDY COMPARING A ONCE-DAILY LAMA AND LABA FIXED-DOSE COMBINATION, ANORO ELLIPTA AND STIOLTO RESPIMAT FOR COPD​.GSK - ‍ENDPOINT WAS MET, AND UMEC/VI DEMONSTRATED SUPERIORITY TO TIO/OLO, WITH A DIFFERENCE IN TREATMENT EFFECT OF 52ML ON TROUGH FEV1 AT WEEK EIGHT ​.GLAXOSMITHKLINE PLC - ‍MOST FREQUENTLY-REPORTED ADVERSE EVENTS WERE UPPER RESPIRATORY TRACT INFECTIONS, COUGH AND DIARRHOEA​.GLAXOSMITHKLINE PLC - ‍BOTH TREATMENTS DEMONSTRATED A COMPARABLE TOLERABILITY AND SAFETY PROFILE​.GLAXOSMITHKLINE PLC - ‍OVERALL INCIDENCE OF ON-TREATMENT ADVERSE EVENTS OF 25% IN UMEC/VI GROUP AND 31% IN TIO/OLO GROUP​.  Full Article

Innoviva reports Q3 adj earnings $0.31/shr
Wednesday, 25 Oct 2017 04:05pm EDT 

Oct 25 (Reuters) - Innoviva Inc :Innoviva reports third quarter 2017 financial results and provides business updates.Q3 adjusted earnings per share $0.31.Q3 earnings per share view $0.31 -- Thomson Reuters I/B/E/S.Innoviva Inc - ‍plans to repurchase up to $80 million of common stock, pursuant to an accelerated share repurchase (ASR) plan​.Innoviva Inc - qtrly ‍total revenue $48.6 million versus $33.3 million.Q3 revenue view $57.2 million -- Thomson Reuters I/B/E/S.  Full Article

GlaxoSmithkline and Innoviva announces positive impact results for Trelegy in COPD
Wednesday, 20 Sep 2017 02:00am EDT 

Sept 20 (Reuters) - GLAXOSMITHKLINE PLC ::POSITIVE IMPACT RESULTS FOR TRELEGY IN COPD.CO, INNOVIVA REPORT POSITIVE HEADLINE RESULTS FROM STUDY SHOWING SINGLE INHALER TRIPLE THERAPY TRELEGY ELLIPTA REDUCED COPD EXACERBATIONS.GLOBAL REGULATORY FILINGS WITH IMPACT STUDY ARE EXPECTED TO COMMENCE IN Q2 OF 2018.  Full Article

GlaxoSmithKline says Trelegy Ellipta once-daily single inhaler triple therapy receives positive opinion from CHMP in Europe
Friday, 15 Sep 2017 02:00am EDT 

Sept 15 (Reuters) - GLAXOSMITHKLINE PLC ::TRELEGY ELLIPTA ONCE-DAILY SINGLE INHALER TRIPLE THERAPY RECEIVES POSITIVE OPINION FROM THE CHMP IN EUROPE FOR APPROPRIATE PATIENTS WITH COPD.TRELEGY ELLIPTA ONCE-DAILY SINGLE INHALER TRIPLE THERAPY RECEIVES POSITIVE OPINION FROM CHMP IN EUROPE FOR APPROPRIATE PATIENTS WITH COPD​.TRELEGY ELLIPTA ONCE-DAILY SINGLE INHALER TRIPLE THERAPY RECEIVES POSITIVE OPINION FROM THE CHMP IN EUROPE FOR APPROPRIATE PATIENTS WITH COPD.  Full Article

Innoviva prices offering of $175 mln of 2.50 pct convertible senior notes
Tuesday, 1 Aug 2017 07:33pm EDT 

Aug 1 (Reuters) - Innoviva Inc ::Innoviva Inc. prices offering of $175 million of 2.50 pct convertible senior notes.  Full Article

Innoviva proposes $175 mln offering of convertible senior notes
Monday, 31 Jul 2017 05:49pm EDT 

July 31 (Reuters) - Innoviva Inc :Innoviva announces proposed offering of $175 million of convertible senior notes.Innoviva Inc - ‍intention to offer, subject to market conditions and other factors, $175 million of convertible senior notes due 2025​.Innoviva Inc - ‍may also purchase shares of its common stock in privately negotiated transactions in connection with offering of notes​.Innoviva-To use net proceeds of offering to redeem on next interest payment date of August 15, 2017 portion of principal outstanding under 2029 notes.Innoviva Inc - notes are being offered in connection with company's previously stated plan to refinance its 9.0% fixed rate term notes due 2029.  Full Article

Innoviva Q2 adjusted earnings per share $0.35
Wednesday, 26 Jul 2017 04:05pm EDT 

July 26 (Reuters) - Innoviva Inc :Innoviva reports strong second quarter 2017 financial results.Q2 adjusted earnings per share $0.35.Q2 earnings per share view $0.27 -- Thomson Reuters I/B/E/S.Q2 earnings per share $0.33.Q2 revenue $58.6 million versus i/b/e/s view $50.5 million.  Full Article

GSK and Innoviva submit EU filing for extended use of Relvar Ellipta
Friday, 21 Jul 2017 09:00am EDT 

July 21 (Reuters) - GlaxoSmithKline plc ::GSK submits EU filing for extended use of Relvar Ellipta in patients with controlled asthma on an ICS/LABA combination.  Full Article

GlaxoSmithKline announces positive results for asthma drug study
Friday, 5 May 2017 07:38am EDT 

May 5 (Reuters) - Glaxosmithkline Plc ::Announced positive results from innovative Salford Lung Study (SLS) in asthma.Relvar Ellipta significantly improved asthma control in Salford Lung Study patients compared with their usual care.Study showed significantly more asthma patients initiated on treatment with Relvar Ellipta achieved improvement in their asthma control.At 24 weeks a significantly higher percentage of patients with asthma achieved better control of their asthma (71 pct) measured by asthma control test (ACT).Statistically significant findings were also seen at 12, 40 and 52 weeks.Serious adverse events of pneumonia by randomised group were reported by 39 patients (ff/vi arm 23, 1 pct; usual care arm 16, <1 pct).  Full Article

Innoviva reports Q1 earnings per share $0.16
Thursday, 27 Apr 2017 04:05pm EDT 

April 27 (Reuters) - Innoviva Inc -:Innoviva reports first quarter 2017 financial results.Q1 adjusted earnings per share $0.19.Q1 earnings per share $0.16.Innoviva Inc - total net revenue for q1 of 2017 was $40.5 million, compared with $24.2 million in q1 of 2016.Royalties earned in q1 2017 of $43.7 million, up 60% from q1 2016.Q1 earnings per share view $0.27, revenue view $47.7 million -- Thomson Reuters I/B/E/S.  Full Article

BRIEF-GSK and Innoviva announce positive data from COPD study

* GSK STUDY DEMONSTRATES SUPERIORITY OF ANORO ELLIPTA TO STIOLTO RESPIMAT IN IMPROVING LUNG FUNCTION IN CHRONIC OBSTRUCTIVE PULMONARY DISEASE